초록접수 현황
| 20F-123 | 구연 발표 |
Adjuvant chemotherapy after esophagectomy for esophageal squamous cell carcinoma with lymph node metastasis
Yeong Jeong Jeon, Hong Kwan Kim, Sumin Shin, Jong Ho Cho, Yong Soo Choi, Jhingook Kim, Jae Ill Zo, Young Mog Shim
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
Purpose : Oncologic efficacy of adjuvant chemotherapy (AC) in patients with node-positive esophageal squamous cell carcinoma (ESCC) is controversial.
Methods : We retrospectively reviewed node-positive ESCC patients who underwent curative-intent esophagectomy with or without AC at our institution between 1994 and 2015. Overall survival (OS) and recurrence-free survival (RFS) were compared between the AC and surgery alone (SA) groups.
Results : A total of 460 patients (AC, 333; SA, 127) were included. The SA group had more elderly patients (64 vs 60 years, p < 0.001) and more comorbidities (p = 0.004) than the AC group. The AC group was associated with more advanced T (p = 0.046) and N stages (p < 0.001). In patients with pT1 stage, there was no difference in OS and RFS between the two groups. Conversely, in patients with pT2 stage, the AC group had better OS than the SA group (71.4 ± 7 vs 50 ± 10.2%, p = 0.011) and in patients with pT3 or higher stage, the AC group had better OS (36.8 ± 3.5 vs 21.2 ± 5.7, p = 0.007) and RFS (34.9 ± 3.6 vs 28.9 ± 7.1, p = 0.035) than the SA group. In multivariable analysis, AC had a favorable effect on both OS (HR 0.562, 95% CI 0.426-0.741; p < 0.001) and RFS (HR 0.702, 95% CI 0.514-0.959; p = 0.026)
Conclusion : Surgery followed by AC may improve survival in node-positive ESCC patients, especially with pathologic T2-4 tumors. Prospective studies on adjuvant chemotherapy are needed in the future.
Methods : We retrospectively reviewed node-positive ESCC patients who underwent curative-intent esophagectomy with or without AC at our institution between 1994 and 2015. Overall survival (OS) and recurrence-free survival (RFS) were compared between the AC and surgery alone (SA) groups.
Results : A total of 460 patients (AC, 333; SA, 127) were included. The SA group had more elderly patients (64 vs 60 years, p < 0.001) and more comorbidities (p = 0.004) than the AC group. The AC group was associated with more advanced T (p = 0.046) and N stages (p < 0.001). In patients with pT1 stage, there was no difference in OS and RFS between the two groups. Conversely, in patients with pT2 stage, the AC group had better OS than the SA group (71.4 ± 7 vs 50 ± 10.2%, p = 0.011) and in patients with pT3 or higher stage, the AC group had better OS (36.8 ± 3.5 vs 21.2 ± 5.7, p = 0.007) and RFS (34.9 ± 3.6 vs 28.9 ± 7.1, p = 0.035) than the SA group. In multivariable analysis, AC had a favorable effect on both OS (HR 0.562, 95% CI 0.426-0.741; p < 0.001) and RFS (HR 0.702, 95% CI 0.514-0.959; p = 0.026)
Conclusion : Surgery followed by AC may improve survival in node-positive ESCC patients, especially with pathologic T2-4 tumors. Prospective studies on adjuvant chemotherapy are needed in the future.
책임저자: Hong Kwan Kim
Department of Thoracic and Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea
발표자: Yeong Jeong Jeon, E-mail : cappuccino1007@gmail.com